



Molecular Detection of *AmpC* Family Genes Encoding Antibiotic Resistance among *Escherichia coli* isolated from Patients with Urinary Tract Infection (UTI) in Najaf Hospitals

Abeer Mohammed Ali AL-karawyi* Salman Aziz AL-Jubouri**
Yassir D. K. Alasadiy*

* Dept. of Biology, College of Science, University of AL-Muthnna

** Dept. of Micro, University of Kufa, College of Medicine

Abstract :

One hundred and thirty significant bacteriuria were detected. The study showed higher incidence of UTI in females (73.08%) than males (26.9%). The *E. coli* isolates which grown on culture of all the 130 urine samples with significant bacteriuria were 60 (46.2%). The isolates which were resistant to ampicillin and amoxicillin 53(88.3%). The ability of *E. coli* isolates to *AmpC* production were tested; the results have revealed that 23 (43.4%) isolates produce *AmpC* β -lactamase. PCR amplification results have shown that eighteen *E. coli* isolates possess *AmpC* β -lactamase gene. The results in this study showed 8 (44.4%) had *bla*_{FOX} gene and 7(38.9%) had *bla*_{CIT} while 5(27.8%) of *E. coli* isolates had *bla*_{DHA} and 9(50%) had *bla*_{EBC} gene.

Key words: Detection *AmpC* β -lactamase *Escherichia coli*, Prevalence *bla*_{EBC} gene, Urinary tract infection

التشخيص الجزيئي للجينات المقاومة *AmpC* المشفرة للمقاومة للمضادات في عزلات بكتريا القولون المعزولة في التهاب المجاري البولية

عبير محمد علي القروي * أ.م.د سلمان عزيز الجبوري **
أ.م.د ياسر دخيل كريمش الأسدي *

* قسم الأحياء، كلية العلوم، جامعة المثنى
** فرع الأحياء المجهرية، كلية الطب، جامعة الكوفة

الخلاصة:

أظهرت النتائج في هذه الدراسة أن 130 من عينات الإدرار المأخوذة من المرضى المشكوك بإصابتهم بالتهاب المسالك البولية كانوا مصابين فعلاً بالبيلة البكتيرية significant bacteriuria. كما أنه عدد عزلات الإشريشيا القولونية التي تم الحصول عليها من 130 عينة إدرار كانت 60 عزلة وكانت هذه العزلات قد خضعت لاختبار الحساسية لكل من المضادين الحبوبين هما الامبيسيلين والاموكسيسيلين وأظهرت النتائج أن 53 منها كانت مقاومة لكلا المضادين. وعندما اختبرت هذه العزلات بواسطة اختبار ثلاثي الأبعاد واختبار الأقراص لمعرفة قدرتها على إنتاج أنزيم ألبينا لاكتاميز أظهرت النتيجة أن 23 عزلة منها أنتجت هذا الإنزيم ولكن عند استخدام تقنية PCR أظهرت النتيجة أن 18 عزلة منها كانت حاملة جين *AmpC* ثم بعد ذلك خضعت لاختبار أربعة جينات من عائلة *AmpC* وهي *bla*_{FOX} و *bla*_{CIT} وكانت نسبها هي 8(44.4%) و 7(38.9%) على التوالي. والجينين الآخرين هما *bla*_{DHA} و *bla*_{EBC} وكانت نسبهما 5(27.8%) و 9(50%) على التوالي.

Introduction:

Urinary tract infection (UTI) is remains one of the most common bacterial infections and second most common infectious disease in the community practice. Approximately about 150 million people were diagnosed with UTI each year (1). Uropathogenic *E. coli* cause 90% of the UTI in anatomically normal, unobstructed urinary tracts.

The bacteria colonize from the feces or perineal region and ascend the urinary tract to the bladder the typical patient with uncomplicated cystitis is a sexually active female who was first colonized in the intestine with UPEC strain.

The organisms are propelled into the bladder from the per urethral region during sexual intercourse, with specific adhesions they are able to colonize the bladder (2). The bladder infection are 14- times more common in females than male which attributed to anatomical differences between the genders women have shorter, less complex urethras than men, and the urethral opening is much closer to the anus, facilitating transfer of uropathogens from the gastrointestinal tract into the urinary tract also absence prostate fluids which has antibacterial characteristics (3).

One of the most important mechanisms of antibiotic resistance in Uropathogenic *E. coli* is the production of *AmpC* β -lactamases (Class C β -lactamases) which are an important group of enzymes that are broadly distributed in the world; it is the second most common β -lactamase group (4). The first bacterial enzyme reported to destroy penicillin was the *AmpC* β -lactamase of *E. coli*, although it had not been so named in 1940 (5). The inducible chromosomal *AmpC* genes were detected on plasmids of *Klebsiella* spp., *E. coli*, or *Salmonella* spp. In *E. coli* *AmpC* is poorly expressed, while in *Klebsiellae* and *Salmonella* species the *AmpC* gene is missing from the chromosome and found on the plasmids (6). Recently, more than 100 different *AmpC* enzymes were

commonly isolated from extended-spectrum cephalosporin-resistant Gram-negative bacteria (7).

Methods:**Collection of specimens**

The present study included collection of 250 urine samples from three hospitals in Najaf (Al-Sader Medical City, Al-Hakeem General Hospital, Al-Furat Teaching Hospital) during the period from (January 2012 to April 2012). Out of the 250 samples 178 were female and 72 were male. The samples were taken by standard mid-stream "clean catch" method from patients with suspected urinary tract infections and each urine sample was collected from patient into a sterile container (8,9). The specimens were transferred immediately to the laboratory for culture and identification.

Isolation and Identification of Bacterial Isolates

The urine sample recovered from patients suspected with bacteruria and divided into two portions. One portion was for the direct microscopic examination, the urine samples were mixed and aliquots centrifuged at 5000 rpm for 5 min. The deposits were examined using both x10 and x40 objectives. Samples with ≥ 10 white blood cells/mm³ were regarded as pyuric (10). A volume of the urine samples were applied to a glass microscope slide, allowed to air dry, stained with gram stain, and examined microscopically (11). The second was cultured firstly on brain heart infusion broth and then sub-cultured on MacConkey agar and Eosin methylene blue agar using standard loop method.

The MacConkey agar is specially made to distinguish lactose fermenting (pink to red colonies) from non lactose fermenting bacteria (colorless or slightly beige) and incubated for overnight at 37°C. The culture results were interpreted as being significant and insignificant bacteriuria, according to the standard bacteriological

tests. A growth of $\geq 10^5$ colony forming units/ml was considered as significant bacteriuria (12,13). The pure cultures were prepared for biochemical tests to differentiate *E. coli* from other *Enterobacteriaceae* depending on biochemical tests (positive for methyl red and indole tests, negative in the Voges-Proskauer, Simmon citrate, and urease tests), acid/acid with gas production in the triple sugar iron test (14).

Detection of AmpC Beta-lactamase

a) Modified Three Dimensional Test (MTDT)

This test was carried out according to Manchanda and Singh (15) and Parveen (16) as follows:

Fresh overnight growth from Muller-Hinton agar plate was transferred to a pre-weighed sterile Eppendorf tube. The tube was weighed again to ascertain the weight of the bacterial mass. The technique was standardized so as to obtain 15 mg of bacterial wet weight for each sample. The growth was suspended in peptone water and pelleted by centrifugation at 3000 rpm for 15 min. Crude enzyme extract was prepared by repeated freeze-thawing approximately 15 cycles. Lawn cultures of *E. coli* ATCC 25922 were prepared on Muller-Hinton agar plates and cefoxitin 30 µg disks were placed on the plate. Linear slits 3 cm were cut using a sterile surgical blade 3 mm away from the cefoxitin disk. Small circular wells were made on the slits at 5 mm distance, inside the outer edge of the slit by stabbing with a sterile pasteur pipette on the agar surface.

The wells could easily be loaded with the enzyme extract 30 µl increments until the well was filled to the top. The plates were kept upright for 5-10 min until the solution dried, and then incubated at 37°C overnight. The isolates showing clear distortion of the zone of inhibition of cefoxitin were taken as AmpC producers. The isolates with no distortion were taken

as AmpC non producers and isolates showing minimal distortion were taken as indeterminate isolates.

b) AmpC Disk Test

All isolates subjected to MTDT were also simultaneously checked by AmpC disk test. A lawn culture of *E. coli* ATCC 25922 was prepared on Muller-Hinton agar plate. Sterile disks 6 mm were moistened with sterile saline 20 µl and inoculated with several colonies of test organism. The inoculated disk was then placed beside a cefoxitin disk almost touching on the inoculated plate. The plates were incubated overnight at 37°C. A positive test appeared as flattening or indentation of the cefoxitin inhibition zone in the vicinity of the test disk. A negative test had an undistorted zone (16,17,18).

Molecular Detection of AmpC

Genomic DNA Mini kit

Bacterial DNA was extracted by using the Genomic DNA Mini kit (Geneaid) according to the manufacturer's instructions.

Multiplex PCR Mixture

All *bla*AmpC gene positive isolates were subjected to four genes family of plasmid mediated AmpC β-lactamase (PABL), by using lyophilized AccuPower® PCR PreMix multiplex PCR protocol. Single reaction (final reaction volume 20 µl) consisted of plasmid mediated AmpC β-lactamase genes primers 10 pmole/µl (consist of forward 1.5 µl and reverse 1.5 µl for each primer), DNA template 5 µl were transferred to AccuPower® PCR tube and the reaction volume completed with 9 µl nuclease free water to 20 µl. The lyophilized blue pellet was dissolved by vortexing and briefly spin down. All materials were mixed in same AccuPower® PCR tube on ice bag under sterile condition.

PCR Thermocycling Conditions

Table (2-1): Programs of PCR thermocycling conditions

Multiplex gene	Temperature (°C)/ Time					Cycle number
	Initial denaturation	Cycling condition			Final extension	
		denaturation	annealing	extension		
<i>blaFOX</i>	94/3min	94/30 sec	64/30 sec	72/1min	72/7min	25
<i>blaCIT</i>	95/2min	95/30sec	61/30sec	72/50sec	72/5min	25
<i>blaEBC</i>	95/2min	95/30 sec	62.6/30sec	72/40sec	72/5min	25
<i>blaDHA</i>	95/2min	95/30sec	61/30 sec	72/50sec	72/5min	25

PCR products were resolved on 1% agarose gels stained with ethidium bromide, and photographed with UV illumination.

Results and Discussion:

Specimens Collection and Identification

The present study included a collection of 250 urine samples from three hospitals in Najaf during the period from(January 2012 toApril 2012). out of the 250 samples processed ; 130 (52 %) showed

significant bacteriuria (table 3-1) ; and 100 (76.9 %) of which showed significant pyuria (when more than 10 polymorphonuclear pus cells/high power field). Atotal of 95 (73.08%) females and 35(26.9%) males had positive urine culture with significant bacteriuria .

Type of culture	No.	Percentage	Female	Male
Significant bacteriuria	130	52%	95 (73.08%)	35 (26.9%)
Non-significant bacteriuria	23	9.2%	12 (52.2%)	11 (47.8%)
Sterile	97	38.8%	71 (73.2%)	26 (26.8%)
Total	250	100%	178 (71.2%)	72 (28.8%)

Table (3-1): Incidence of significant bacteriuria in patients suspected UT

However, the bacterial isolates that obtained as a pure and predominant in growth in urine samples were considered in the present study, all these bacteria were identified based on colonial morphology, and biochemical reactions according to (14,19,20). In the present study, the organisms which grown on

culture of all the 130 urine samples with significant bacteriauria were as follows: 60 (46.2 %) isolates of *E. coli* and 70 (53.8%) were other gram negative and positive bacteria (table 3-2). The *E. coli* isolates were most common pathogens isolated from patients with significant bacteriuria in the group studied .

Bacterial isolate	No. of isolates		Total
	Female	Male	
<i>E. coli</i>	46(76.7%)	14 (23.3%)	60 (46.2%)
other Gram(-) and(+) isolates	54 (77.1%)	16 (22.9%)	70 (53.8%)
Total	100(76.9%)	30(23.1%)	130(100%)

Table (3-2): Distribution of etiological agents in patients with significant Bacteriuria .

Detection of *AmpC* β -lactamases-Producing Isolates

In the present study, an attempt was made to evaluate the frequency of β -lactam resistant in all *E. coli* (n=60) isolates which obtained from urine of patients with significant bacteriuria. The isolates were screened on Muller-Hinton agar supplemented with ampicillin and amoxicillin (each alone) .Such two β -lactam antibiotics were selected because they are the most commonly used antibiotics in the therapy of bacterial infections, compared to other β -lactam antibiotics. A part from their therapeutic

usage, these antibiotics can provide a comprehensive primary screening of β -lactam resistant isolates because the isolate that is resistant to carbenicillin and cephalosporin is already resistant to ampicillin and amoxicillin(4,2). The results obtained in this study revealed that 53 (88.3%) of *E. coli* isolates were resistant to both ampicillin and amoxicillin. The results revealed that 23 (43.4%) of *E. coli* isolates producing *AmpC* from the total number of 53 *E. coli* isolates which were isolated from urinary tract infections (Figure 1). The results indicated that all 23 isolates have plasmid originated *AmpC* (Figure 2).





Figure (3-1): A-Three dimensional test, EC10, EC6 and EC1gave positive results and EC20 isolates in gave negative results in this test.



Figure(3-2): B- AmpC disc test , and EC10 gave positive results this test.

These findings are in agreement with those of Tenja (22). who found that the chromosomally encoded *AmpC* β -lactamases are very rare. Another study showed the susceptibility to third generation cephalosporins (e.g. ceftazidime and cefixime) serve as a poor marker for the identification of *AmpC*-producing bacteria (23). As well as the plasmid mediated *AmpC*- producing isolates can some times appear falsely susceptible to the third generation cephalosporins(24). The bacterial isolates producing PABs have been found to be

now wide spread for example, In the United States, occurrence rates of PABs for *E. coli* were (4%)(25), In switzerland , (0.2%) of PABs for *E. coli* [26], In China, found that only (2.0%) *E. coli* isolates were detected as PABs (27) .

Molecular Detection of *AmpC* β -lactamase

Polymerase chain reaction technique has been used to amplify genes which encoding the *AmpC* β -lactamase. The results clarify that 18 isolates carrying *AmpC* gene (Figure 3-3and figure 3-4).




Figure (3-3): Ethidium bromide-stained agarose gel of multiplex PCR amplified products from extracted DNA of *bla*_{AmpC} positive *E. coli* isolates and amplified with *bla*_{CIT} and *bla*_{FOX} genes primers (forward and reverse). Lane (L), DNA molecular size marker (2000-bp ladder), Lanes (EC3, 8, 9, 11, 12, 14 and 15) of *E. coli* isolates showed positive results with *bla*_{CIT} (462 bp) genes and Lanes (EC1, 4, 6, 11, 13, 14, and 15) showed positive results with *bla*_{FOX} (190 bp) genes .




Figure (3-4): Ethidium bromide-stained agarose gel of multiplex PCR amplified products from extracted DNA of *bla*_{AmpC} positive *E. coli* isolates and amplified with *bla*_{DHA} and *bla*_{EBC} genes primers (forward and reverse). Lane (L), DNA molecular size marker (2000-bp ladder), Lanes (EC3, 4 and 5) of *E. coli* isolates showed positive results with *bla*_{DHA} (405 bp) genes and Lanes (EC1, 3, 4, 7, 8, 9, 10, 13 and 14) showed positive results with *bla*_{EBC} (302 bp) genes .

The results in this study showed 8 (44.4%) had a bands compatible with *bla*FOX gene and this result was higher than the results which reported in Pakistan 2/121 (1.7%) *E. coli* isolates showing FOX *ampC* β -lactamase (28). Another study in Korea, *E. coli* resistance due to FOX enzyme have increasingly been noted, and a study performed in 2003 showed that high portion (53.4%) of FOX resistance in *E. coli* was due to plasmid-borne AmpC β -lactamase production (29). whereas the CIT family (CMY2-7, LAT14 and BIL-1) was presented in (38.9%) of *bla*AmpC positive *E. coli* isolates. This prevalent rate was agreement with those reported by Tan *et al* who found that among 174 isolates of AmpC positive *E. coli*, this bacteria was most microorganism expressed CIT enzyme 67 (39%) (30).

This investigation revealed that among the AmpC β -lactamase producers, 5 (27.8%) showed the presence of *bla* (DHA-1 and -2). This represents the first report of *bla*DHA in the Najaf. In accordance with Mohamudha *et al* who observed that DHA group genes were predominantly in *E. coli* 24/60 (40%) followed by in *K. pneumoniae* 19 (44.1%) (31).

Additionally, a new plasmid-mediated AmpC β -lactamase, which was designated EBC (ACT-1 and MIR-1) family, was found in Najaf hospitals. Among the 18 *E. coli* isolates with *bla*AmpC gene, 9 (50%) had *bla*EBC type gene. In comparison with other studies, reported that EBC enzyme was the most common gene (21/57, 36.3%) among plasmid mediated β -lactamases producing enteric bacteria (32).

References:

1- Akram, M., Shahid, M. and Khan, A. U. (2007). Etiology and Antibiotic Resistance Patterns of Community-acquired Urinary Tract Infections in J N M

C Hospital Aligarh, India. J. Ann. Clin. Microbiol. Antimicrob. **6** (4): 1476-0711.

2- Todar, K. (2002). Pathogenic *E. coli* Todar's Oline Textbook of Bacteriology. university of wisconsin-madison, Department of bacteriology.

3- Barrios, A. F., Zuo, R., Ren, D. and Wood, T. K. (2006). Hha, YbaJ, and OmpA regulate *Escherichia coli* K12 biofilm formation and conjugation plasmids abolish motility. J. Biotechnol. Bioeng. **93**(1):188-200.

4- Bush, K., Jacoby, G.A. and Medeiros, A. A. (1995). A functional classification scheme for β -lactamases and its correlation with molecular structure. J. Antimicrob. Agents and Chemother. **39**(6): 1211-1233.

5- Jacoby, G.A. (2009). AmpC β -Lactamases. J. Clin. Microbiol. Rev. **22**(1):161-82.

6- Philippon, A., Arlet, G. and Jacoby, G.A. (2002). Plasmid-determined AmpC-type β -lactamases. J. Antimicrob. Agents Chemother. **46**(1):1-11.

7- Jacoby, G.A. and Bush, K. (2009). Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant β -lactamases from <http://www.lahey.org>.

8- Karlowsky, J. A., Hoban, D.J., Decorby, M.R., Laing, N. M. and Zhanel, G. G. (2006). Fluoroquinolone-resistant urinary isolates of *Escherichia coli* from outpatients are frequently multi-drug: Results from the North American urinary tract infection collaborative alliance-quinolone resistance study. J. Antimicrob. Agents Chemother. **50**(6): 2251-2254

9- Solberg, O. O., Ajiboye, R. and Riley, L.W. (2006). Origin of class 1 and 2

integron and gene cassettes in a population-based sample of uropathogenic *Escherichia coli*. J. Clin. Microbiol. **44**(4): 1347-1351.

10- Smith, P. J., Morris, A. J. and Reller, L. B. (2003). Predicting Urine Culture Results by Dipstick Testing and Phase Contrast Microscopy. J. Pathol. **35**(2):161-165.

11- Kolawole, A. S., Kolawole, O. M., Kandaki-Olukemi, Y. T., Babatunde, S. K., Durowade, K. A. and Kolawole, C. F. (2009). Prevalence of urinary tract infections (UTI) among patients attending Dalhatu Araf Specialist Hospital, Lafia, Nasarawa State, Nigeria. Int. J. Medicinal Med. Sci. **1**(5):163-167 .

12- Bailey and Scottes (1994). Diagnostic microbiology, 9 th ed. Ellen Jo Baron, Lance R., Sydney M. Finegold. Mosby-Year Book, USA.

13- Balentine, J. R. and Stöppler, M.C. (2012) . Urinary tract infection. J. emedicine health. P. 1-14.

14- MacFaddin, J.F. (2000). Biochemical tests for identification of medical bacteria. 3rd ed. Lippincott Williams and Wilkins, USA.

15- Manchanda, V. and Singh, N. P. (2003). Occurrence and detection of AmpC β lactamases among Gram-negative clinical isolates using a modified three dimensional test at Guru Tegh Bahadur Hospital, Delhi. India. J. Antimicrob. **51**(2): 415-418.

16- Parveen, M.R., Harish, B.N. and Parija, S.C. (2010). AmpC β -lactamase among Gram-negative clinical isolates from A tertiary hospital, South India. Brazilian J. of Microbiol. **41**(3):596-602.

17- Singhal, S., Mathor, T., Khan, S., Upadhyay, D. J., Chugh, S., Gaiind, R. and

Rattan, A, (2005). Evaluation of methods for AmpC beta lactamases in Gram-negative isolates from tertiary care hospital. Ind. J. Microbiol. **23**(2): 120-124.

18- Basak, S., Khodke, M., Bose, S. and Mallick, S. K. (2009). Inducible AmpC β -lactamase producing *Pseudomonas aeruginosa* isolates in a rural hospital of central India. J. of Clin. and Diag. Res. **3**(6):1921-1927.

19- Cowan, S.T. (1985).Cowan and Steels Manual for Identification of Medical Bacteria. 2 nd ed., Cambridge Univ. Press, Cambridge, London. pp. 138-139.

20-Holt, J.H. and Krieg, N.R. (1994). Bergey's Manual of determinative bacteriology. 9th ed. Baltimore: Williams and Wilkins, 80-179, 88-187.

21-Al-Charrakh, A. (2005) . Bcteriological and genetic study on extended-spectrum β -lactamases and bacteriocins of *Klebsiella* isolated from Hilla city. Ph.D. Thesis. College of Scince Baghdad University.

22- Taneja, N., Rao, P., Arora, J. and Dogra, A. (2008). Occurrence of ESBL & AmpC β -lactamases & susceptibility to newer antimicrobial agents in complicated UTI. Indian J. Med. Res. **127**(1): 85-88.

23-Coudron, P. E. (2005). Inhibitor-based methods for detection of plasmid mediated AmpC beta-lactamases in *Klebsiella spp.*, *Escherichia coli* and *Proteus mirabilis*. J. Clin. Microbiol. **43**(8): 4163-4167.

24- Black JA, Moland ES and Thomson KS. (2005). AmpC disk test for detection of plasmid- mediated AmpC- β lactamases in *Enterobacteriaceae* lacking chromosomal AmpC- β -lactamases. J Clin Microbiol; **43** : 3110-3.

- 25-Al-varez**, M., Tran, J.H., Chow, N. and Jacoby, G.A.(2004). Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. *J. Antimicrob. Agents Chemother.* **48**(2):533–7.
- 26-Adler**, H., Fenner, L., Walter, P., Hohler, D., Schultheiss, E., Oezcan, S., and Frei, R.(2008).Plasmid-mediated AmpC β -lactamases in *Enterobacteriaceae* lacking inducible chromosomal ampC genes: prevalence at a Swiss university hospital and occurrence of the different molecular types in Switzerland. *J. Antimicrob. Chemother.* **61**(2):457–8.
- 27- Ding**, H., Yang, Y., Lu, Q., Wang, Y., Chen, Y., Deng, L., Zhang, H., Wang, C., Liu, L., Xu, X., Wang, L. and Shen, X. (2008) . The prevalence of plasmid-mediated AmpC β -lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from five children's hospitals in China. *Eur. J. Clin. Microbiol. Infect. Dis.* **27**(10):915–21.
- 28- Hussain**, M., Hasan, F., Ali Shah, A., Hameed, A., Jung1, M., Rayamajhi, N., Cha1, S. and Yoo1, H. (2011). Prevalence of Class A and AmpC β -Lactamases in Clinical *Escherichia coli* Isolates from Pakistan Institute of Medical Science, Islamabad, Pakistan. *J. Infect. Dis.* **64**(3): 249-252.
- 29- Lee**, K., Lim, C. H., Cho, J. H., Lee,W. G., Uh,Y., Kim, H. J., Yong, D., Chong, Y. and the KONSAR group. (2006). High prevalence of ceftazidime-resistant *Klebsiella pneumoniae* and increase of imipenem-resistant *Pseudomonas aeruginosa* and *Acinetobacter spp.* in Korea: a KONSAR program in 2004. *J. Yonsei. Med.* **47**(5): 634-645.
- 30- Tan**, T.Y., Ng, L.S.Y., He, J., Koh, T.H. and Hsu, L.Y. (2009). Evaluation of screening methods to detect plasmid-mediated AmpC in *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*. *J. Antimicrob. Agents Chemother.* **53**(1):146–149.
- 31- Mohamudha**,P. R., Harish, B. N. and Parija, S.C. (2012). Molecular description of plasmid-mediated AmpC β -lactamases among nosocomial isolates of *Escherichia coli* & *Klebsiella pneumoniae* from six different hospitals in India. *J. Med.Res.* **135**(1) : 114-119.
- 32- Cocks**, S. and Vaughan, C. (2009). First Validation of D69C Mast Disks AmpC Detection Discs. www.mastgrp.com.